Pliant Therapeutics, Inc. (NASDAQ:PLRX) Insider Hans Hull Sells 15,936 Shares

Pliant Therapeutics, Inc. (NASDAQ:PLRX) insider Hans Hull sold 15,936 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the transaction, the insider now directly owns 211,558 shares of the company’s stock, valued at approximately $2,369,449.60. This trade represents a 7.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Pliant Therapeutics Price Performance

PLRX stock opened at $10.92 on Friday. The stock’s 50 day moving average price is $13.14 and its 200 day moving average price is $13.05. The firm has a market cap of $664.48 million, a P/E ratio of -3.27 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics, Inc. has a 1 year low of $10.22 and a 1 year high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.04. On average, sell-side analysts expect that Pliant Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $40.50.

Institutional Investors Weigh In On Pliant Therapeutics

Hedge funds have recently modified their holdings of the company. Great Point Partners LLC lifted its stake in shares of Pliant Therapeutics by 42.4% during the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after buying an additional 785,000 shares during the period. Renaissance Technologies LLC raised its holdings in Pliant Therapeutics by 233.8% in the 2nd quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock valued at $2,724,000 after acquiring an additional 177,469 shares during the last quarter. Checkpoint Capital L.P. lifted its stake in shares of Pliant Therapeutics by 63.7% during the 3rd quarter. Checkpoint Capital L.P. now owns 380,000 shares of the company’s stock worth $4,260,000 after purchasing an additional 147,800 shares during the period. Polar Asset Management Partners Inc. boosted its holdings in shares of Pliant Therapeutics by 265.2% during the third quarter. Polar Asset Management Partners Inc. now owns 170,200 shares of the company’s stock worth $1,908,000 after purchasing an additional 123,600 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Pliant Therapeutics in the second quarter valued at $865,000. 97.30% of the stock is owned by institutional investors and hedge funds.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.